Genopathy
Gene-Disorder Association · Article
Gene
LPL
Lipoprotein Lipase
Manually curatedApproved treatment annotated
Association Review

In brief

The association between LPL (Lipoprotein Lipase) and Hyperlipoproteinemia, Type I is well established and manually curated, with its 5 contributing sources — 3 of them expert-curated — recording a known molecular basis, pathogenic variants, and causative variation.

Sources 5
Clinical variants 223
Symptoms 40
Compounds 1
Trials 4of 10 via LPL compounds
Publications 138
01
At a glance

Association overview

A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.

Request access
02
Provenance

Evidence and sources

5 sources

Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.

Request access
03
LPL

The gene

2 source summaries

A gene summary alongside the source descriptions it was distilled from.

Request access
04
Hyperlipoproteinemia, Type I

The disorder

12 database identifiers

The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).

Request access
05
Phenotype

Clinical features

27 clinical features

The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.

Request access
06
ClinVar and variant evidence

Genetic basis

223 clinical variants

ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.

Request access
07
Genomic context

Regulatory context

1 regulatory element

GeneHancer regulatory elements for the pair, with coordinates, score, element type and supporting literature.

Request access
08
Mechanism overlap

Shared mechanisms

1 shared pathway

Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.

Request access
09
Interventions

Therapeutics

1 compound or drug

Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.

Request access
10
Human studies

Clinical trials

10 clinical trials

Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.

Request access
11
Literature

Reading

138 publications

Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.

Request access
12
Provenance

References & sources

25 references

Every source and publication cited across this dossier, as one numbered reference list.

Request access